Chemotherapy in the Treatment of Ovarian Psammocarcinoma: A Case Report and Review of the Literature
|Adil Debbagh1,2*, Mohamed Reda Khmamouche1, Mohamed Allaoui3, Mohamed Ichou1 and Hassan Errihani2|
|1Medical Oncology Department, Military Hospital Mohamed V, Rabat, Morocco|
|2Medical Oncology Department, National Institute of Oncology, Rabat, Morocco|
|3Anatomopathology Department, Military Hospital Mohamed V, Rabat, Morocco|
|Corresponding Author :||Adil Debbagh
Medical Oncology Department
National Institute of Oncology
Military Hospital Mohamed V, Rabat, Morocco
E-mail: [email protected]
|Received February 16, 2013; Accepted Septeber 13, 2013; Published September 16, 2013|
|Citation: Debbagh A, Khmamouche MR, Allaoui M, Ichou M, Errihani H (2013) Chemotherapy in the Treatment of Ovarian Psammocarcinoma: A Case Report and Review of the Literature. J Clin Case Rep 3:303. doi:10.4172/2165-7920.1000303|
|Copyright: © 2013 Debbagh A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Introduction: Psammocarcinoma is a rare form of epithelial serous ovarian carcinoma characterized by extensive formation of psammoma bodies, invasion of ovarian stroma, peritoneum or intraperitoneal viscera, and moderate cytological atypia. These tumors represent a real problem of the diagnostic, and the role of chemotherapy is not yet clearly demonstrated.
Case presentation: We herein report a case of psammocarcinoma of ovary with peritoneal carcinosis in a forty year old Moroccan female. The patient underwent optimal surgical debulking and nine courses of chemotherapy with carboplatinum and paclitaxel with a complete response. The prognosis for this type of ovarian cancer is unclear, but it appears to be better than other forms of epithelial ovarian cancer.
Conclusion: The psammocarcinome is a rare entity, majority of patients are diagnosed at an advanced stage. The role of chemotherapy is poorly defined; some authors have their patients treated by neoadjuvant or adjuvant chemotherapy.
We currently lack evidence of increasing the benefits that can bring chemotherapy in the management of advanced ovarian psammocarcinomas. Only trials in wide yard can answer this question.